WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $22.6 million in its third quarter.
On a per-share basis, the Washington-based company said it had a loss of 37 cents.
The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
The biopharmaceutical company posted revenue of $69.8 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $65.9 million.
Vanda expects full-year revenue of $240 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VNDA at https://www.zacks.com/ap/VNDA
